Spero Biopharma

Company Overview

Snapshot

Founded in June 2019 by Moti Hacham and Marta Weinstock-Rosin, Spero Biopharma operates with 1–10 employees. The company is developing an innovative drug to prevent the deterioration from mild cognitive impairment to Alzheimer's disease.

Business overview

Spero Biopharma is a Health Tech & Life Sciences company focused on developing pharmaceutical solutions for neurological disorders. The company's core product is Ladostigil, a drug designed to treat mild cognitive impairment and prevent its progression to Alzheimer's disease. Spero Biopharma operates within the Pharmaceuticals, Neurology, and Drug Discovery sectors, targeting the healthcare and life sciences markets, particularly in the United States.

Company Intelligence Q&A

What is Spero Biopharma's primary focus?

Spero Biopharma is focused on the prevention and treatment of Alzheimer's disease through the development of innovative pharmaceutical solutions.

Who founded Spero Biopharma?

Spero Biopharma was founded by Moti Hacham and Marta Weinstock-Rosin in June 2019.

What is Ladostigil?

Ladostigil is Spero Biopharma's drug designed to treat mild cognitive impairment before it progresses to Alzheimer's disease.

In which sectors does Spero Biopharma operate?

Spero Biopharma operates in the Health Tech & Life Sciences sector, with a focus on Pharmaceuticals, Neurology, and Drug Discovery.

What is the current product stage of Ladostigil?

Ladostigil is currently in the clinical trial stage of development, as of March 2021, focusing on its efficacy in preventing the progression from mild cognitive impairment to Alzheimer's disease.